lncRNA ACTA2-AS1 inhibits malignant phenotypes of gastric cancer cells

Liu, Zhi-Ping; Hu, Kaibing; Wang, Xiang; Zhang, Youqian; Wang, Weiping; Wu, Yin-Di

doi:10.1515/med-2021-0406

Cited by 7 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Li et al (2022) found that KCNQ1OT1/miR-556-3p/CLIC1 axis may promote GC growth and metastasis. Liu et al (2022) found that ACTA2-AS1 (lncRNA) suppressed the malignant phenotype of GC cells by targeting the miR-378a-3p/PLCXD2 axis as ceRNA. Liu et al (2022) revealed the potential molecular mechanism of RBMS1 to promote GC metastasis, suggesting that RBMS1 may be a potential therapeutic target.…”

Section: Discussionmentioning

confidence: 99%

Identification of the KCNQ1OT1/ miR-378a-3p/ RBMS1 Axis as a Novel Prognostic Biomarker Associated With Immune Cell Infiltration in Gastric Cancer

Yue

Liang

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Gastric cancer (GC) is the second leading cause of cancer-related mortality and the fifth most common cancer worldwide. However, the underlying mechanisms of competitive endogenous RNAs (ceRNAs) in GC are unclear. This study aimed to construct a ceRNA regulation network in correlation with prognosis and explore a prognostic model associated with GC.Methods: In this study, 1,040 cases of GC were obtained from TCGA and GEO datasets. To identify potential prognostic signature associated with GC, Cox regression analysis and the least absolute shrinkage and selection operator (LASSO) regression were employed. The prognostic value of the signature was validated in the GEO84437 training set, GEO84437 test set, GEO15459 set, and TCGA-STAD. Based on the public databases, TargetScan and starBase, an mRNA-miRNA-lncRNA regulatory network was constructed, and hub genes were identified using the CytoHubba plugin. Furthermore, the clinical outcomes, immune cell infiltration, genetic variants, methylation, and somatic copy number alteration (sCNA) associated with the ceRNA network were derived using bioinformatics methods.Results: A total of 234 prognostic genes were identified. GO and GSEA revealed that the biological pathways and modules related to immune response and fibroblasts were considerably enriched in GC. A nomogram was generated to provide accurate prognostic outcomes and individualized risk estimates, which were validated in the training, test dataset, and two independent validation datasets. Thereafter, an mRNA-miRNA-lncRNA regulatory network containing 4 mRNAs, 22 miRNAs, 201 lncRNAs was constructed. The KCNQ1OT1/hsa-miR-378a-3p/RBMS1 ceRNA network associated with the prognosis was obtained by hub gene analysis and correlation analysis. Importantly, we found that the KCNQ1OT1/miR-378a-3p/RBMS1 axis may play a vital role in the diagnosis and prognosis of GC patients based on Cox regression analyses. Furthermore, our findings demonstrated that mutations and sCNA of the KCNQ1OT1/miR-378a-3p/RBMS1 axis were associated with increased immune infiltration, while the abnormal upregulation of the axis was primarily a result of hypomethylation.Conclusion: Our findings suggest that the KCNQ1OT1/miR-378a-3p/RBMS1 axis may be a potential prognostic biomarker and therapeutic target for GC. Moreover, such findings provide insights into the molecular mechanisms of GC pathogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of the KCNQ1OT1/ miR-378a-3p/ RBMS1 Axis as a Novel Prognostic Biomarker Associated With Immune Cell Infiltration in Gastric Cancer

Yue

Liang

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…They protect the body from tumor invasion, block tumor growth, and promote the normal development of cells ( Kontomanolis et al, 2020 ). LncRNA actin alpha 2, smooth muscle antisense RNA 1 (ACTA2-AS1) can suppress malignant phenotypes of GC cells as it can function as a ceRNA to bind to miR-378a-3p and antagonize the inhibitory impacts of miR-378a-3p on the expression of phosphatidylinositol-specific phospholipase C X domain containing 2 (PLCXD2) ( Liu et al, 2022 ). PLCXD2 is linked to an enhanced risk of esophageal squamous cell carcinoma in the Han Chinese population ( Wang et al, 2019c ).…”

Section: Lncrnas Regulate Emt-induced Metastasis In Gc Through Spongi...mentioning

confidence: 99%

Epithelial-mesenchymal transition-related long noncoding RNAs in gastric carcinoma

Feng

Wang

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

As an evolutionarily phenotypic conversion program, the epithelial-mesenchymal transition (EMT) has been implicated in tumour deterioration and has facilitated the metastatic ability of cancer cells via enhancing migration and invasion. Gastric cancer (GC) remains a frequently diagnosed non-skin malignancy globally. Most GC-associated mortality can be attributed to metastasis. Recent studies have shown that EMT-related long non-coding RNAs (lncRNAs) play a critical role in GC progression and GC cell motility. In addition, lncRNAs are associated with EMT-related transcription factors and signalling pathways. In the present review, we comprehensively described the EMT-inducing lncRNA molecular mechanisms and functional perspectives of EMT-inducing lncRNAs in GC progression. Taken together, the statements of this review provided a clinical implementation in identifying lncRNAs as potential therapeutic targets for advanced GC.

show abstract

“…A previous study identified a series of differently expressed ncRNAs in breast cancer from the Cancer Genome Atlas, including 55 lncRNAs, 88 miRNAs, and 1465 mRNAs, where lncRNA ACTA2-AS1 (lncRNA actin alpha 2, smooth muscle antisense RNA1) was found to be downregulated [ 7 ]. The function of ACTA2-AS1 has been illustrated in prior studies, such as colon adenocarcinoma, lung adenocarcinoma, and gastric cancer, with abnormal expression [ 8 – 10 ]. The upregulation of miR-532-5p in TNBC was leaked out in a previous expression profile of miRNAs in breast cancer at different onset stages [ 11 ], and its enhanced effect was also revealed in the cellular processes of breast cancer [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

lncRNA ACTA2-AS1 predicts malignancy and poor prognosis of triple-negative breast cancer and regulates tumor progression via modulating miR-532-5p

Peng¹,

Huang²,

Wang³

2022

BMC Mol and Cell Biol

View full text Add to dashboard Cite

Background Dysregulation of ACTA2-AS1 and miR-532-5p and their functions in various cancers have been widely reported. Their potential of serving as biomarkers in triple-negative breast cancer (TNBC) remains unknown. This study aimed to evaluate the function of ACTA2-AS1 and miR-532-5p and their potential of serving as biomarkers in TNBC. Results The TNBC tissues were collected from 119 patients, where the reduced level of ACTA2-AS1 and increased level of miR-532-5p were observed by PCR and showed a significantly negative correlation (P < 0.001). Both ACTA2-AS1 and miR-532-5p were closely associated with the malignant development and poor prognosis of TNBC patients. Moreover, in TNBC cell, overexpressing ACTA2-AS1 was found to suppress cell proliferation and metastasis, which was reversed by the upregulation of miR-532-5p. Conclusions ACTA2-AS1 and miR-532-5p could act as biomarkers of TNBC predicting the progression and prognosis of patients. ACTA2-AS1 served as a tumor suppressor of TNBC which was mediated by miR-532-5p.

show abstract

lncRNA ACTA2-AS1 inhibits malignant phenotypes of gastric cancer cells

Cited by 7 publications

References 57 publications

Identification of the KCNQ1OT1/ miR-378a-3p/ RBMS1 Axis as a Novel Prognostic Biomarker Associated With Immune Cell Infiltration in Gastric Cancer

Identification of the KCNQ1OT1/ miR-378a-3p/ RBMS1 Axis as a Novel Prognostic Biomarker Associated With Immune Cell Infiltration in Gastric Cancer

Epithelial-mesenchymal transition-related long noncoding RNAs in gastric carcinoma

lncRNA ACTA2-AS1 predicts malignancy and poor prognosis of triple-negative breast cancer and regulates tumor progression via modulating miR-532-5p

Contact Info

Product

Resources

About